Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

VJOncology

- PMLiVE

Alnylam swaps Sanofi for Regeneron as R&D partner

Novel alliance between two biotechs

- PMLiVE

#OrkambiNow?

After a long standoff over CF treatment Orkambi, is a deal imminent?

scientific services porterhouse medical

Rewarding excellence within Porterhouse Medical’s scientific services team.

At Porterhouse Medical, we are very proud of our hard-working teams and are always delighted to recognise career progression within the agency. With this in mind, we are thrilled to...

Porterhouse Medical Group

Roche Basel Switzerland

Roche says ‘discovery proteomics’ is heading for clinical trials

Tech has potential to identify novel biomarkers

- PMLiVE

Sanofi exits R&D pact with Alnylam on rare disease

Exit also frees up $700m equity investment

How to go BIG with your pharma exhibition stand design

At Apex, we believe that you don’t need to go for a huge exhibition stand if you want to get noticed. In fact, with a talented exhibition stand design team...

Apex Events and Exhibitions

- PMLiVE

Leader named for NHS digital transformation unit, but scepticism persists

NHS managers question logic of another authority

- PMLiVE

Celgene files luspatercept ahead of key merger vote

Analysts predict peak revenues of $2bn

Evolve, evolve, evolve; a call to action to all leaders in the healthcare industry

Challenges for tomorrow's leaders

- PMLiVE

Novartis and Amgen come to blows over migraine partnership

Amgen seeks to terminate contract

- PMLiVE

Amazon launches first Alexa health services

Has been granted permission to transmit patient data

- PMLiVE

Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)

Authors: Keir LoIacono, John Rodriguez, Daniel J. O’Connor, James R. Nitzkorski, MD*, Christopher G. Twitty, PhDAffiliations: OncoSec Medical Incorporated, San Diego, CA, and Pennington, NJ, *Division of Surgical Oncology, Vassar...

Oncosec

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links